Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 + Dalpiciclib vs Fulvestrant + Dalpiciclib in Advanced Breast Cancer
NCT07354022Phase 3Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07354022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354022.